Testicular Germ Cell Tumor Clinical Trial
Official title:
Phase II Study Of Arsenic Trioxide In Patients With Refractory Germ Cell Malignancies
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing
so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of arsenic trioxide in treating men who
have germ cell cancer that has not responded to previous treatment.
OBJECTIVES:
- Determine the response rate (confirmed complete and partial responses) in men with
refractory testicular or extragonadal germ cell malignancies treated with arsenic
trioxide.
- Determine the overall and progression-free survival of patients treated with this drug.
- Determine the qualitative and quantitative toxic effects of this drug in these
patients.
- Assess the biomarker response rate in patients with elevated biomarkers treated with
this drug.
OUTLINE: This is a multicenter study.
Patients receive arsenic trioxide IV over 1-2 hours on days 1-5. Courses repeat every 28
days for up to 3 years in the absence of disease progression or unacceptable toxicity.
Patients who achieve a confirmed complete or partial response receive up to 3 additional
courses past response.
Patients are followed every 2 months for 3 years or until disease progression.
PROJECTED ACCRUAL: A total of 20-40 patients will be accrued for this study within 10-40
months.
;
Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT00788125 -
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
|
Phase 1/Phase 2 | |
Withdrawn |
NCT00006126 -
Peripheral Stem Cell Transplantation in Treating Patients With Melanoma or Small Cell Lung, Breast, Testicular, or Kidney Cancer That is Metastatic or That Cannot Be Treated With Surgery
|
Phase 1 | |
Completed |
NCT00003173 -
High-Dose Thiotepa Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Solid Tumors
|
Phase 2 | |
Completed |
NCT00002596 -
Combination Chemotherapy With or Without Bone Marrow or Stem Cell Transplantation in Treating Men With Untreated Germ Cell Tumors
|
Phase 3 | |
Not yet recruiting |
NCT03448822 -
Sentinel Lymph Node Procedure in Testicular Germ Cell Tumour
|
||
Completed |
NCT01433224 -
Studying Biomarkers in Samples From Younger Patients With Malignant Germ Cell Tumor Progression
|
N/A | |
Recruiting |
NCT01172912 -
High-Dose Chemotherapy and Stem Cell Transplant in Treating Patients With Metastatic Germ Cell Tumors That Have Not Responded to First-Line Therapy
|
Phase 2 | |
Completed |
NCT00293384 -
Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant
|
N/A | |
Active, not recruiting |
NCT00003643 -
Combination Chemotherapy in Treating Men With Germ Cell Cancer
|
Phase 2/Phase 3 | |
Completed |
NCT00003107 -
Interleukin-12 in Treating Patients With Hematologic Cancers or Solid Tumors
|
Phase 1 | |
Completed |
NCT00019331 -
Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors
|
Phase 2 | |
Completed |
NCT00002515 -
Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Rare Cancer
|
Phase 2 | |
Recruiting |
NCT06133699 -
Sentinel Lymph Node Biopsy in Stage AI-IIA Germ Cell Tumors
|
N/A | |
Recruiting |
NCT05670938 -
Follow-up After Surgery for Testicular Cancer
|
||
Active, not recruiting |
NCT00104676 -
Combination Chemotherapy in Treating Patients With Stage II or Stage III Germ Cell Tumors
|
Phase 3 | |
Recruiting |
NCT00551122 -
Gemcitabine, Paclitaxel, Ifosfamide, and Cisplatin in Treating Patients With Progressive or Relapsed Metastatic Germ Cell Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT00002508 -
Combination Chemotherapy Followed by Bone Marrow or Stem Cell Transplantation in Treating Patients With Relapsed or Refractory Germ Cell Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT00003800 -
Diagnostic Study of Patients With Stage I Testicular Cancer
|
N/A | |
Terminated |
NCT05012397 -
Milademetan in Advanced/Metastatic Solid Tumors
|
Phase 2 | |
Completed |
NCT00007813 -
Peripheral Stem Cell Transplantation Plus Chemotherapy in Treating Patients With Malignant Solid Tumors
|
Phase 1 |